Total Payments
$1,006
2022 Payments
$452.56
Companies
6
Transactions
20
Medicare Patients
469
Medicare Billing
$35,113
Payment Breakdown by Category
Food & Beverage$799.53 (79.5%)
Travel$206.21 (20.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $799.53 | 19 | 79.5% |
| Travel and Lodging | $206.21 | 1 | 20.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $432.69 | 4 | $0 (2022) |
| GlaxoSmithKline, LLC. | $263.52 | 3 | $0 (2021) |
| Novo Nordisk Inc | $211.11 | 7 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $42.09 | 2 | $0 (2021) |
| Genentech USA, Inc. | $32.07 | 2 | $0 (2021) |
| ARBOR PHARMACEUTICALS, INC. | $24.26 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $452.56 | 5 | Biohaven Pharmaceutical Holding Company Ltd. ($432.69) |
| 2021 | $553.18 | 15 | GlaxoSmithKline, LLC. ($263.52) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/07/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Travel and Lodging | Cash or cash equivalent | $206.21 | General |
| Category: PRIMARY CARE | ||||||
| 05/07/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | Cash or cash equivalent | $101.48 | General |
| Category: PRIMARY CARE | ||||||
| 05/07/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| Category: PRIMARY CARE | ||||||
| 05/07/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: PRIMARY CARE | ||||||
| 03/01/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Diabetes | ||||||
| 12/14/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: Diabetes | ||||||
| 12/02/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Virology & Specialty Care | ||||||
| 11/11/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: Virology & Specialty Care | ||||||
| 10/26/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $6.93 | General |
| Category: Diabetes | ||||||
| 09/30/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: RESPIRATORY | ||||||
| 09/23/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: RESPIRATORY | ||||||
| 09/02/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Diabetes | ||||||
| 06/17/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Diabetes | ||||||
| 06/08/2021 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $98.82 | General |
| Category: Diabetes | ||||||
| 05/26/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $20.15 | General |
| Category: NEUROSCIENCE | ||||||
| 05/25/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Diabetes | ||||||
| 05/12/2021 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/28/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $123.03 | General |
| Category: RESPIRATORY | ||||||
| 04/13/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: NEUROSCIENCE | ||||||
| 03/02/2021 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | Food and Beverage | In-kind items and services | $11.21 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 121 | 128 | $36,332 | $9,960 |
| 2022 | 8 | 348 | 385 | $75,640 | $25,152 |
Total Patients
469
Total Services
513
Medicare Billing
$35,113
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 46 | 46 | $14,674 | $3,538 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 32 | $7,040 | $2,075 | 29.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 22 | $5,852 | $2,052 | 35.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $6,766 | $1,915 | 28.3% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 11 | 11 | $2,000 | $380.82 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 74 | 80 | $21,280 | $8,286 | 38.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 90 | 105 | $23,100 | $7,350 | 31.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $12,736 | $3,878 | 30.4% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 66 | 81 | $8,100 | $2,788 | 34.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 28 | 28 | $8,932 | $2,604 | 29.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 12 | 12 | $691.56 | $128.71 | 18.6% |
| 81003 | Automated urinalysis test | Office | 2022 | 27 | 28 | $420.00 | $61.77 | 14.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 19 | 19 | $380.00 | $56.19 | 14.8% |
About Jadran Dychioco, NP-C
Jadran Dychioco, NP-C is a Emergency healthcare provider based in Valencia, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/16/2018. The National Provider Identifier (NPI) number assigned to this provider is 1174094239.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jadran Dychioco, NP-C has received a total of $1,006 in payments from pharmaceutical and medical device companies, with $452.56 received in 2022. These payments were reported across 20 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($799.53).
As a Medicare-enrolled provider, Dychioco has provided services to 469 Medicare beneficiaries, totaling 513 services with total Medicare billing of $35,113. Data is available for 2 years (2022–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency
- Other Specialties Family
- Location Valencia, CA
- Active Since 12/16/2018
- Last Updated 02/01/2022
- Taxonomy Code 163WE0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174094239
Products in Payments
- NURTEC ODT (Drug) $432.69
- TRELEGY ELLIPTA (Drug) $263.52
- Ozempic (Drug) $182.77
- TRINTELLIX (Drug) $42.09
- Xofluza (Drug) $32.07
- RYBELSUS (Drug) $28.34
- Edarbi (Drug) $24.26
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.